Trial Profile
A Propensity Score-Matched Analysis Comparing Bleeding Rates and Clinical Outcomes Between Ticagrelor and Prasugrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2017
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary) ; Ticagrelor (Primary)
- Indications Acute coronary syndromes
- Focus Adverse reactions
- 30 Jun 2017 New trial record